Prohibition didn’t stop marijuana use. It stopped marijuana research. | Ruth Fisher

This article examines how cannabis prohibition has fundamentally impeded scientific research on the drug’s therapeutic potential and safety profile, preventing the accumulation of evidence needed to inform clinical practice. By restricting cannabis to Schedule I status federally, the regulatory framework has created barriers to conducting rigorous clinical trials, leaving physicians with limited high-quality data on efficacy, dosing, drug interactions, and adverse effects compared to other pharmaceuticals. The prohibition-based approach has paradoxically failed to reduce cannabis use while simultaneously blocking the research infrastructure that could optimize therapeutic applications and minimize harms. For clinicians, this evidence gap means prescribing or recommending cannabis often occurs without the robust clinical literature available for most approved medications, making informed, evidence-based decision-making difficult. The practical takeaway is that clinicians should advocate for research accessibility and remain aware that current cannabis use patterns in their patient populations reflect public demand despite an evidence void, highlighting the urgent need for policy reform to enable adequate clinical investigation.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: